



Bal Pharma Limited

01.04.2016

✓ To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

To,
The Manager-Listing
Bombay Stock Exchange Ltd
Mumbai.

Dear Sir,

Sub:- Disclosure under Regulation 30 of SEBI (Substantial Acquisition of Shares and Take overs) Regulations, 2011.

With reference to the above, we submit to the exchange disclosures received from the promoters and promoter group of the Company in compliance with the provisions of Regulation 30(2) of SEBI (Substantial Acquisition of Shares and Take overs) Regulations, 2011, for the financial year ended 31.03.2016.

Please take the same on record.

Thanking you.

For Bal Pharma Limited

Sanjay Agarwal
Authorized Signatory



Intertek



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057/48

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813/19 Fax : 41570820

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Shailesh Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.


1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : m) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR n) Name of the promoter(s), member of promoter group and PAC with him.	SHAILESH SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : ee) Shares ff) Voting Rights (otherwise then by shares) gg) Warrants hh) Convertible Securities ii) Any other instrument that would entitle the holder to receive shares in the TC.	1270759	9.87%	9.87%
Total	1270759	9.87%	9.87%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore
Date : 31.03.2016

Signature

Shailesh Siroya

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,


Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,


Anita Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.


1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
c) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR d) Name of the promoter(s), member of promoter group and PAC with him.	NA ANITA SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
f) Shares	1018540	7.91%	7.91%
g) Voting Rights (otherwise then by shares)			
h) Warrants			
i) Convertible Securities			
j) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	1018540	7.91%	7.91%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore
Date : 31.03.2016

Signature

ANITA SIROYA

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Subbarao Prasanna

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : q) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR r) Name of the promoter(s), member of promoter group and PAC with him.	SUBBA RAO PRASANNA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : oo) Shares pp) Voting Rights (otherwise then by shares) qq) Warrants rr) Convertible Securities ss) Any other instrument that would entitle the holder to receive shares in the TC.	20200	0.16%	0.16%
Total	20200	0.16%	0.16%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.


Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2016

Signature


Subbarao Prasanna

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Shrenik D Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
o) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.			
OR			
p) Name of the promoter(s), member of promoter group and PAC with him.	SHRENIK D SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
jj) Shares	374700	2.91%	2.91%
kk) Voting Rights (otherwise then by shares)			
ll) Warrants			
mm) Convertible Securities			
nn) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	374700	2.91%	2.91%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.


Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2016

Signature


Shrenik D Siroya

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,


Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Monica Surana

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
<p>k) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.</p> <p>OR</p> <p>l) Name of the promoter(s), member of promoter group and PAC with him.</p>	MONICA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
<p>z) Shares</p> <p>aa) Voting Rights (otherwise then by shares)</p> <p>bb) Warrants</p> <p>cc) Convertible Securities</p> <p>dd) Any other instrument that would entitle the holder to receive shares in the TC.</p>	179909	1.40%	1.40%
Total	179909	1.40%	1.40%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2016

Signature

Monica Surana

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



~~Dilip Surana~~ (HUF)

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : s) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR t) Name of the promoter(s), member of promoter group and PAC with him.	DILIP SURANA(HUF)		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : tt) Shares uu) Voting Rights (otherwise then by shares) vv) Warrants ww) Convertible Securities xx) Any other instrument that would entitle the holder to receive shares in the TC.	169995	1.32%	1.32%
Total	169995	1.32%	1.32%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2016

Signature

Dilip Surana(HUF)

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,


Dilip Surana

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.


1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : g) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR h) Name of the promoter(s), member of promoter group and PAC with him.	DILIP SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : p) Shares q) Voting Rights (otherwise then by shares) r) Warrants s) Convertible Securities t) Any other instrument that would entitle the holder to receive shares in the TC.	474994	3.69%	3.69%
Total	474994	3.69%	3.69%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore
Date : 31.03.2016

Signature

Dilip Surana

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



ANAND SURANA

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
<p>a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.</p> <p>OR</p> <p>b) Name of the promoter(s), member of promoter group and PAC with him.</p>	ANAND SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	525686	4.08 %	4.08%
b) Voting Rights(otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	525686	4.08 %	4.08%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2016

Signature



ANAND SURANA

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Archana Surana

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
e) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR f) Name of the promoter(s), member of promoter group and PAC with him.	ARCHANA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
k) Shares	284996	2.21%	2.21%
l) Voting Rights (otherwise then by shares)			
m) Warrants			
n) Convertible Securities			
o) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	284996	2.21%	2.21%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore
Date : 31.03.2016

Signature



Archana Surana

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA


With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,

For, MICRO LABS LIMITED

For MICRO LABS LIMITED

Authorized Signatory  Company Secretary

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : i) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR j) Name of the promoter(s), member of promoter group and PAC with him.	MICRO LABS LIMITED		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : u) Shares v) Voting Rights (otherwise then by shares) w) Warrants x) Convertible Securities y) Any other instrument that would entitle the holder to receive shares in the TC.	1310836	10.18%	10.18%
Total	1310836	10.18%	10.18%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore
Date : 31.03.2016

For, MICRO LABS LIMITED

Authorized Signatory Company Secretary

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,

JIVI D- SIROYA

Jivi Dheerajmal Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders : e) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR f) Name of the promoter(s), member of promoter group and PAC with him.	JIVI DHEERAJMAL SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of : k) Shares l) Voting Rights (otherwise then by shares) m) Warrants n) Convertible Securities o) Any other instrument that would entitle the holder to receive shares in the TC.	46080	0.36%	0.36%
Total	46080	0.36%	0.36%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2016

Signature

Jivi D-Siroya
Jivi Dheerajmal Siroya

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,

Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Chandraprakash Dheerajmal Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) AND 30(2) OF SEBI (Substantial Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
c) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR d) Name of the promoter(s), member of promoter group and PAC with him.	NA CHANDRAPRAKASH DHEERAJMAL SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
f) Shares	486420	3.78%	3.78%
g) Voting Rights (otherwise then by shares)			
h) Warrants			
i) Convertible Securities			
j) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	486420	3.78%	3.78%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.

Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore
Date : 31.03.2016

Signature



Chandraprakash Dheerajmal Siroya

To,

31.03.2016

The Manager- Listing
NSE
Mumbai

Dear Sir,


Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulation 2011

Ref:- Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial Year ending 31.03.2016 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation 2011.

Thanking You,



Anita Chandraprakash Siroya

Copy to:

Bal Pharma Limited
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

Acquisition of Shares and Takeovers) REGULATIONS, 2011.

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Names of the stock exchanges where the shares of the TC are listed	a) Bombay Stock Exchange Ltd, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders :			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR b) Name of the promoter(s), member of promoter group and PAC with him.	ANITA CHANDRAPRAKASH SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of shares.	% w.r.t total share/voting capital wherever applicable.	% of the total diluted share/voting capital of the TC(*)
As on March 31 st of the year, holding of :			
a) Shares	122687	0.95%	0.95%
b) Voting Rights (otherwise then by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	122687	0.95%	0.95%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of outstanding convertible securities / warrants into equity shares of the TC.


Note :

1. In case of promoter(s) making disclosures under Regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place : Bangalore

Date : 31.03.2016

Signature



Anita Chandraprakash Siroya